Skip to main content
. 2019 Dec 2;4:191. [Version 1] doi: 10.12688/wellcomeopenres.15603.1

Figure 4.

Figure 4.

Comparison of NEJM-2018, Walker-2015 and candidate panel 3 (CP3) on the Prospective dataset for ( a) first-line drugs and ( b) second-line drugs. Counts of susceptible samples are shown on the left, broken down for each tool/panel into those correctly identified as susceptible (in the colour of the tool/panel), those falsely identified as resistant coloured red and no-calls coloured grey. Similarly, resistant samples are shown on the right, with those correctly identified as resistant coloured by the tool/panel, those falsely identified as susceptible in red, and no-calls in grey. Note that second-line drugs were not considered in NEJM-2018. E, ethambutol; H, isoniazid; Z, pyrazinamide; R, rifampicin; Am, amikacin; Cm, capreomycin; Cfx, ciprofloxacin; Km, kanamycin; Mfx, moxifloxacin; Ofx, ofloxacin; S, streptomycin.